Teva Pharmaceutical Industries Ltd Stock Price Today (NSE: IL&FSTRANS)

Teva Pharmaceutical Industries Ltd

2.320.03 (1.28%)
Market Closed

Fundamental Score

...

Teva Pharmaceutical Industries Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Teva Pharmaceutical Industries Ltd share price today is 2.32, down 1.28% on NSE/BSE as of 8 June 2026. Teva Pharmaceutical Industries Ltd (IL&FSTRANS) is a Small-cap company in the Civil Construction sector with a market capitalisation of 93.05 (Cr). The 52-week high for IL&FSTRANS share price is 4.40 and the 52-week low is 1.75.

Teva Pharmaceutical Industries Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
2.68
Low
2.22
Volume
49.3K
Change
-6.97%

Teva Pharmaceutical Industries Ltd share price chart: -6.97% return over the past month. 52-week high ₹4.40, 52-week low ₹1.75.

Teva Pharmaceutical Industries Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
2.352.392.302.3128.62K (Cr)
2.302.362.232.3233.38K (Cr)
2.262.312.162.2543.72K (Cr)
2.302.432.222.2748.06K (Cr)
2.342.372.302.3323.51K (Cr)
2.262.362.262.3429.71K (Cr)
2.452.452.302.3139.59K (Cr)
2.352.482.322.4054.60K (Cr)
2.312.392.252.3751.84K (Cr)
2.322.322.252.2910.00K (Cr)

Teva Pharmaceutical Industries Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
2.302.392.232.31+0.43%
2.382.682.162.25-5.46%
1.842.761.752.34+27.17%
2.482.481.841.84-25.81%
2.742.942.422.45-10.58%
3.003.042.542.73-9.00%
2.993.122.422.90-3.01%
3.183.182.732.95-7.23%
3.143.252.883.03-3.50%
3.103.342.933.06-1.29%
3.323.462.843.19-3.92%
4.154.403.063.32-20.00%

Returns & Performance

Return on Equity (ROE)

N/A

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

-18.13%

Returns generated on total capital deployed

Poor

Oper. Profit Margin (5Y Avg)

2.29%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Teva Pharmaceutical Industries Ltd Valuation Check

Price to Earnings (P/E)

N/A

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

18.93x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

73.22%

% shares held by company founders/management

Poor

FII Holding

0.00%

% shares held by foreign institutional investors

Poor

DII Holding

0.42%

% held by domestic mutual funds, LIC, banks

Poor

Promoter Pledged %

98.23%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

-1100.85%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

7.66%

Revenue growth vs same quarter last year

Poor

Revenue Growth (5-Year CAGR)

-51.00%

Compounded annual revenue growth over 5 years

EPS Growth (5-Year CAGR)

N/A

Earnings per share growth over 5 years

Net Profit Growth (5-Year CAGR)

N/A

Compounded annual net profit growth over 5 years

Balance Sheet Health

Debt to Equity Ratio

N/A

Total debt ÷ equity. Below 0.5 = financially healthy

Poor

Interest Coverage Ratio

-10.02x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

847.07 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Teva Pharmaceutical Industries Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of IL&FSTRANS across key market metrics for learning purposes.

Positive Indicators

2 factors identified

Strong Cash Generation (₹847.07 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Balanced Promoter Holding (73.22%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Risk Factors

8 factors identified

Suboptimal ROCE (-18.13%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

Margin Pressure Concerns (2.29%)

Observation: Operating margins are below industry standards.

Analysis: OPM <5% may indicate pricing pressures or cost management challenges.

Profit Decline Concern (-1100.85%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes.

Limited Growth History (-51.00% CAGR)

Observation: Below-average 5-year sales growth trajectory.

Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.

Weak Interest Coverage (-10.02x)

Observation: Limited ability to service debt obligations from earnings.

Analysis: Low interest coverage raises concerns about financial stability.

Limited Institutional Interest (FII+DII: 0.42%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

High Share Pledging Risk (98.23%)

Observation: Significant promoter share pledging creates potential overhang.

Analysis: High pledging levels may create selling pressure during market downturns.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Teva Pharmaceutical Industries Ltd vs Civil Construction Peers

Peer Comparison - Civil Construction

Compare Teva Pharmaceutical Industries Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
0/100
2
₹93.05
-18.13%
Poor
-51.00%
Poor
0.00%
35.9/100
3989
₹560453.09
34.9
Average
16.55%
Good
14.49%
Average
1.3
Average
9.73%
Good
11.95%
Good
0.83%
34.9/100
239
₹67085.37
59.1
Average
14.01%
Average
14.72%
Average
0.5
Good
11.11%
Good
6.52%
Good
0.53%
60.3/100
104
₹31859.97
47.7
Average
25.54%
Excellent
33.17%
Excellent
0.0
Excellent
51.02%
Excellent
8.28%
Good
0.57%
24.4/100
22
₹26046.27
29.8
Average
5.91%
Poor
7.82%
Poor
1.0
Average
7.82%
Good
2.13%
Average
0.70%
29.9/100
1290
₹20171.65
24.6
Average
9.96%
Poor
15.95%
Good
0.7
Good
8.45%
Good
11.98%
Good
0.76%
48.5/100
497
₹18483.64
27.1
Average
12.02%
Average
17.98%
Good
0.9
Good
0.06%
Average
12.80%
Good
0.79%
14.1/100
326
₹15033.09
29.9
Average
11.06%
Average
19.59%
Good
0.7
Good
14.18%
Good
4.78%
Average
0.61%
30.2/100
135
₹14995.61
25.0
Average
11.33%
Average
11.60%
Average
0.8
Good
8.27%
Good
14.82%
Good
1.66%
60.7/100
1047
₹14797.54
33.2
Average
21.78%
Excellent
27.64%
Excellent
0.5
Excellent
37.51%
Excellent
26.03%
Excellent
0.23%
66.3/100
1072
₹13872.92
31.1
Average
12.81%
Average
16.54%
Good
0.0
Excellent
18.85%
Excellent
21.09%
Excellent
0.75%

Teva Pharmaceutical Industries Ltd Quarterly Performance

Latest quarterly metrics for IL&FSTRANS — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

7.66%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

-1100.85%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

-51.00%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

N/A

Compounded annual net profit growth over 5 years

Teva Pharmaceutical Industries Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for IL&FSTRANS — calculated from daily price history

39RSI 14
Neutral — RSI 39

Momentum is balanced — neither overbought nor oversold.

SMA 50
2
▲ Price above SMA 50 — Short-term bullish
SMA 200
3
▼ Price below SMA 200 — Long-term downtrend
30-Day Avg Volume
49K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Teva Pharmaceutical Industries Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Teva Pharmaceutical Industries Ltd (IL&FSTRANS) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Teva Pharmaceutical Industries Ltd

About IL&FSTRANS (Teva Pharmaceutical Industries Ltd)

Teva Pharmaceutical Industries Ltd is a global pharmaceutical titan, renowned for its extensive portfolio of generic and specialty medicines. With a presence spanning continents, T...eva operates a vast network of manufacturing facilities and research and development centers dedicated to producing affordable and accessible healthcare solutions. From complex generics that challenge the status quo to innovative branded therapies addressing critical medical needs, Teva strives to improve patient outcomes worldwide. Their commitment to quality and compliance is paramount, ensuring that every product meets the highest standards of safety and efficacy. This global footprint demands a strong operational backbone, including robust supply chains and logistical networks that allow for the timely distribution of medications to healthcare providers and patients. IL&FSTRANS, a key player in civil construction, focuses on building and maintaining vital transport networks. Imagine a tapestry of asphalt stretching across vast landscapes, connecting bustling urban centers and remote rural communities – that is the work of IL&FSTRANS. They engineer and oversee the development of highways that hum with the passage of commerce, soaring flyovers that untangle congested city streets, and sturdy bridges that span formidable rivers. Beyond concrete and steel, they contribute to the very arteries of movement that enable economic growth and social connection. The company's commitment extends to the ongoing care of these vital routes, providing essential maintenance and toll collection services to ensure their long-term viability and efficiency. IL&FSTRANS are not just builders; they are caretakers of infrastructure, responsible for keeping transportation flowing smoothly. From the initial blueprint to the final coat of paint, they manage every aspect of these intricate projects, ensuring that each structure meets stringent safety standards and environmental regulations. Their expertise extends beyond traditional roadwork to include modern transit systems like metro rail projects and efficient city bus networks. With a commitment to sustainable practices, they incorporate innovative design and materials to minimize environmental impact. Ultimately, their work empowers the efficient movement of people and goods, fostering progress and connectivity across communities and regions.

Company Details

Symbol:IL&FSTRANS
Industry:Civil Construction
Sector:Civil Construction

Key Leadership

Mr. Milind Ramesh Gandhi
CFO, VP of Finance/Accounts
Mr. Krishna D. Ghag
VP, Compliance Officer & Company Secretary
Mr. Manish Kumar Agarwal B.E.
Senior Vice President

IL&FSTRANS Share Price: Frequently Asked Questions

What is the current share price of Teva Pharmaceutical Industries Ltd?

Teva Pharmaceutical Industries Ltd (IL&FSTRANS) trades at ₹2.32 on NSE and BSE. Market cap ₹93.05 (Cr). Educational data only.

What is the P/E ratio of Teva Pharmaceutical Industries Ltd?

Teva Pharmaceutical Industries Ltd has a P/E of N/Ax vs industry average 18.93x.

What is the Bull Run score for Teva Pharmaceutical Industries Ltd?

Teva Pharmaceutical Industries Ltd has a Bull Run score of 0/100 based on 25+ financial parameters.

Does Teva Pharmaceutical Industries Ltd pay dividends?

Teva Pharmaceutical Industries Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Teva Pharmaceutical Industries Ltd?

Teva Pharmaceutical Industries Ltd has ROE of N/A. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Teva Pharmaceutical Industries Ltd?

Teva Pharmaceutical Industries Ltd has debt-to-equity of N/A.

Is Teva Pharmaceutical Industries Ltd a good investment?

Bull Run gives Teva Pharmaceutical Industries Ltd a score of 0/100. This is not investment advice — consult a SEBI-registered advisor.